CN1317030C - 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病 - Google Patents

用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病 Download PDF

Info

Publication number
CN1317030C
CN1317030C CNB028042964A CN02804296A CN1317030C CN 1317030 C CN1317030 C CN 1317030C CN B028042964 A CNB028042964 A CN B028042964A CN 02804296 A CN02804296 A CN 02804296A CN 1317030 C CN1317030 C CN 1317030C
Authority
CN
China
Prior art keywords
application
lhrh antagonist
methyl
continue
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028042964A
Other languages
English (en)
Chinese (zh)
Other versions
CN1575185A (zh
Inventor
J·恩格尔
R·弗格里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of CN1575185A publication Critical patent/CN1575185A/zh
Application granted granted Critical
Publication of CN1317030C publication Critical patent/CN1317030C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CNB028042964A 2001-04-30 2002-04-27 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病 Expired - Fee Related CN1317030C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
US60/287,434 2001-04-30

Publications (2)

Publication Number Publication Date
CN1575185A CN1575185A (zh) 2005-02-02
CN1317030C true CN1317030C (zh) 2007-05-23

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028042964A Expired - Fee Related CN1317030C (zh) 2001-04-30 2002-04-27 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病

Country Status (27)

Country Link
US (1) US7288517B2 (OSRAM)
EP (1) EP1392348B1 (OSRAM)
JP (1) JP2004529207A (OSRAM)
KR (1) KR20040000446A (OSRAM)
CN (1) CN1317030C (OSRAM)
AT (1) ATE400287T1 (OSRAM)
AU (1) AU2002310788B2 (OSRAM)
BG (1) BG108339A (OSRAM)
BR (1) BR0209290A (OSRAM)
CA (1) CA2444876A1 (OSRAM)
CZ (1) CZ20033167A3 (OSRAM)
DE (1) DE60227507D1 (OSRAM)
DK (1) DK1392348T3 (OSRAM)
ES (1) ES2307760T3 (OSRAM)
HU (1) HUP0400067A2 (OSRAM)
IL (1) IL156777A0 (OSRAM)
MX (1) MXPA03008666A (OSRAM)
NO (1) NO20034322D0 (OSRAM)
NZ (1) NZ544417A (OSRAM)
PL (1) PL362319A1 (OSRAM)
PT (1) PT1392348E (OSRAM)
RU (1) RU2319501C2 (OSRAM)
SI (1) SI1392348T1 (OSRAM)
SK (1) SK14512003A3 (OSRAM)
UA (1) UA80679C2 (OSRAM)
WO (1) WO2002102401A1 (OSRAM)
ZA (1) ZA200305326B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
CN1186326C (zh) 2000-07-05 2005-01-26 山之内制药株式会社 丙－1,3－二酮衍生物
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
WO2005118556A1 (ja) * 2004-06-04 2005-12-15 Astellas Pharma Inc. プロパン－１，３－ジオン誘導体又はその塩
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
SI1864976T1 (sl) 2005-03-31 2012-12-31 Astellas Pharma Inc. Propan-1,3-dionski derivat ali njegova sol
WO2008046919A2 (en) * 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
CA2699100A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009033765A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
AU710926B2 (en) * 1996-05-20 1999-09-30 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
AU767440B2 (en) * 1999-05-14 2003-11-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo(1,2-A)pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
JP2003512379A (ja) * 1999-10-15 2003-04-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
CA2406832A1 (en) 2000-04-13 2002-10-10 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
CN1186326C (zh) * 2000-07-05 2005-01-26 山之内制药株式会社 丙－1,3－二酮衍生物

Also Published As

Publication number Publication date
UA80679C2 (en) 2007-10-25
NZ544417A (en) 2008-03-28
ATE400287T1 (de) 2008-07-15
PL362319A1 (en) 2004-10-18
ES2307760T3 (es) 2008-12-01
CA2444876A1 (en) 2002-12-27
US20020177556A1 (en) 2002-11-28
HK1072000A1 (en) 2005-08-12
DE60227507D1 (de) 2008-08-21
JP2004529207A (ja) 2004-09-24
SI1392348T1 (sl) 2008-12-31
NO20034322L (no) 2003-09-26
US7288517B2 (en) 2007-10-30
ZA200305326B (en) 2003-07-30
BG108339A (bg) 2004-11-30
IL156777A0 (en) 2004-02-08
CN1575185A (zh) 2005-02-02
NO20034322D0 (no) 2003-09-26
EP1392348A1 (en) 2004-03-03
EP1392348B1 (en) 2008-07-09
RU2003134949A (ru) 2005-02-10
DK1392348T3 (da) 2008-09-29
KR20040000446A (ko) 2004-01-03
MXPA03008666A (es) 2004-10-15
CZ20033167A3 (cs) 2004-08-18
WO2002102401A1 (en) 2002-12-27
SK14512003A3 (sk) 2004-08-03
BR0209290A (pt) 2004-07-13
RU2319501C2 (ru) 2008-03-20
AU2002310788B2 (en) 2007-04-05
PT1392348E (pt) 2008-09-09
HUP0400067A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
CN1317030C (zh) 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病
US6444665B1 (en) Method for treating pain
US6939853B2 (en) Combined use of a GLP-1 compound and another drug for treating dyslipidemia
US20100184690A1 (en) Combined Use Of A GLP-1 Compound And A Modulator Of Diabetic Late Complications
EP2671584A2 (en) Compositions and methods for treating disorders associated with salt or fluid retention
JP2020040971A (ja) 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP1012188A1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
AU2002310788A1 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
JP2010517987A (ja) 塩基性ペプチド及びその複合型抗細菌−抗真菌剤としての使用
US20090054319A1 (en) Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders
US6437093B1 (en) Methods of treatment comprising administration of Substance P
CA2173839C (en) Transferrin compositions to alleviate the side effects of cytotoxic drugs
CN101522194A (zh) 肾功能障碍预防/治疗剂
HK1072000B (en) Treatment of alzheimer's diseases with intemediate doses of lhrh antagonists
KR960033468A (ko) 혈전용해 치료를 받지않은 환자에서 히루딘 및 아세틸살리실산으로 급성 심근 경색을 치료하는 방법
JP4287523B2 (ja) 抗腫瘍剤
DE60308710T2 (de) Pharmazeutische zusammensetzung mit einem retro-inverso isomerpeptid
JP2004359675A (ja) 脳卒中の治療および予防剤
KR20200143917A (ko) 물질 p를 유효 성분으로 포함하는 대동맥 박리 질환 또는 혈관 및 판막 석회화 예방 또는 치료용 조성물
EP0480458A2 (en) Process for the preparation of pharmaceutical compositions containing Viminol useful in the treatment of drug dependences
EP2421547A1 (en) Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1072000

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee